The appropriateness of enoxaparin use in Lebanese hospitals: a quality evaluation study
- PMID: 21909665
- DOI: 10.1007/s11096-011-9559-1
The appropriateness of enoxaparin use in Lebanese hospitals: a quality evaluation study
Abstract
Background: Although, guidelines for the appropriate use of enoxaparin are published, yet the extent of their implementation in clinical practice is still questionable. Furthermore, the optimal dosing of enoxaparin in special populations such as renal insufficiency and obesity remains controversial. In the Middle East, there are insufficient data on the appropriateness of enoxaparin use in different indications.
Objective: (1) To assess the appropriateness of enoxaparin dosing and duration per indication in compliance with the recommended guidelines and their impact on safety and efficacy outcomes in Lebanese health care centers. (2) To evaluate the influence of the hospital type (teaching vs. non-teaching) on the extent of compliance with established guidelines.
Setting: Seventeen health care centers in Lebanon, including teaching and non-teaching hospitals.
Methods: An observational, cross-sectional, multicenter study was conducted in 17 Lebanese hospitals. Data on demographics, indication, dosing regimen and clinical outcomes were collected. The appropriateness of dosing practices was determined as per the ACCP guidelines and the FDA dosing recommendations.
Main outcome measure: The appropriateness of enoxaparin dosing was compared across different hospital type and among special populations including severe renal insufficiency and very obese patients.
Results: Of the 463 patients who participated in the study, 40% received improper enoxaparin dosing, which was mostly observed in the VTE prophylaxis group (41.6%, P < 0.001). When comparing the overall dosing practices in Lebanese hospitals, there was no statistically significant difference in the correctness of enoxaparin dosing between teaching and non-teaching hospitals (61.6% vs. 58.2%, P = 0.449), respectively. Only 11.5% of renally impaired patients and 59.4% of obese patients received correct doses.
Conclusion: This study highlighted the improper practice and thus the need of implementation of clinical practice guidelines for the dosing of enoxaparin, in Lebanese hospitals.
Similar articles
-
An evaluation of practice pattern for venous thromboembolism prevention in Lebanese hospitals.J Thromb Thrombolysis. 2009 Aug;28(2):192-9. doi: 10.1007/s11239-008-0298-7. Epub 2008 Dec 27. J Thromb Thrombolysis. 2009. PMID: 19110614
-
Prescribing patterns and outcomes of enoxaparin for anticoagulation of atrial fibrillation.Pharmacotherapy. 2003 May;23(5):651-8. doi: 10.1592/phco.23.5.651.32208. Pharmacotherapy. 2003. PMID: 12741440 Clinical Trial.
-
Review of current evidence available for guiding optimal Enoxaparin prophylactic dosing strategies in obese patients-Actual Weight-based vs Fixed.Crit Rev Oncol Hematol. 2017 May;113:191-194. doi: 10.1016/j.critrevonc.2017.03.022. Epub 2017 Mar 22. Crit Rev Oncol Hematol. 2017. PMID: 28427508 Review.
-
Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients.Ann Pharmacother. 2017 Apr;51(4):323-331. doi: 10.1177/1060028016683970. Epub 2016 Dec 15. Ann Pharmacother. 2017. PMID: 28228055 Review.
-
Prescribing of proton pump inhibitors for gastrointestinal bleeding prophylaxis in the Lebanese outpatient setting: patterns, compliance with guidelines and risks.Int J Pharm Pract. 2019 Aug;27(4):386-392. doi: 10.1111/ijpp.12537. Epub 2019 Apr 3. Int J Pharm Pract. 2019. PMID: 30942513
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical